Source comparison
Does BPC-157 Work for Ligament Healing?: Protocol Comparison
Mechanism VEGF/FGF-2 upregulation, angiogenesis, collagen type I gene expression Rest, ice, compression, NSAIDs. Symptom management, no growth factor modulation Autologous growth factors (PDGF, TGF-β, VEGF) released from concentrated platelets BPC-157 shows st
This comparison does not assign a generated winner or score.
- Mechanism
- VEGF/FGF-2 upregulation, angiogenesis, collagen type I gene expression
- Rest, ice, compression, NSAIDs. Symptom management, no growth factor modulation
- Autologous growth factors (PDGF, TGF-β, VEGF) released from concentrated platelets
- BPC-157 shows stronger preclinical angiogenesis data than PRP but lacks human trial validation
- Healing Timeline (Animal Data)
- 60–72% faster tendon repair, 78% tensile strength recovery by day 21
- 52% tensile strength by day 21 in control groups
- 30–50% improvement in healing rates in human trials (ACL, patellar tendon)
- BPC-157 outperforms controls in rats; PRP has established human efficacy data
- Administration Route
- Subcutaneous injection near injury site, 200–500 mcg daily for 14–28 days
- Oral/topical anti-inflammatories, physical therapy, bracing
- Injection directly into injured tissue, 1–3 sessions spaced 2–4 weeks apart
- Localized delivery matters for both. Systemic peptides less effective than site-specific dosing
- Human Clinical Data
- None. All evidence is preclinical animal models
- Decades of clinical use, well-established recovery timelines
- Multiple Phase III trials, FDA-cleared devices, published human outcomes
- PRP has regulatory approval and human trial backing; BPC-157 does not
- Cost & Accessibility
- $50–$150/month (research supply, not medical-grade)
- $0–$50 (OTC NSAIDs, insurance-covered PT)
- $500–$2,500/session (3 sessions typical, insurance rarely covers)
- BPC-157 is cheapest but legally restricted; PRP is expensive but clinically validated